Zhenhong Zhu

Dr. Zhenhong Zhu


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2022 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
HZHongrui Zhang
Hongrui Zhang
XWXinyi Wang
Xinyi Wang
WCWeiwei Chen
Weiwei Chen
YYYixuan Yang
Yixuan Yang
YWYu Wang
Yu Wang
ZZZhenhong Zhu
Zhenhong Zhu

1 March 2022 in Canadian Journal of Microbiology
Verified
Journal Article
Closed access
HZHongrui Zhang
Hongrui Zhang
WCWeiwei Chen
Weiwei Chen
XWXinyi Wang
Xinyi Wang
YLYongquan Li
Yongquan Li
ZZZhenhong Zhu
Zhenhong Zhu
The purpose of this study was to explore the function of the MarR family regulator slnO. Additionally, a high-yield strain of salinomycin was constructed using combined regulation strategies. First, the slnO gene overexpression strain (GO) was constructed in Streptomyces albus. Compared to the wild-type (WT) strain, salinomycin production in the GO strain increased by approximately 28%. Electrophoretic mobility gel shift assays (EMSAs) confirmed that the SlnO protein can bind specifically to the intergenic regions of slnN-slnO, slnQ-slnA1, and slnF-slnT. qRT-PCR experiments also showed that slnA1, slnF, and slnT1 were significantly upregulated, whereas the expression level of the slnN gene was downregulated in the GO strain. Second, the slnN gene deletion strain (slnNDM) was used as the starting strain, and the pathway-specific gene slnR in the salinomycin gene cluster was overexpressed in slnNDM. This new strain was named ZJUS01. The yield of salinomycin in the ZJUS01 strain was 25% and 56% higher than those in the slnNDM and WT strains, respectively. The above results indicate that the slnO gene has a positive regulatory effect on the biosynthesis of salinomycin. Meanwhile, the yield of salinomycin can be greatly increased by manipulating multiple transcriptional regulations.

1 September 2021 in Protein Expression and Purification
Verified
Journal Article
Closed access
WCWei-Wei Chen
Wei-Wei Chen
HZHong-Rui Zhang
Hong-Rui Zhang
ZHZhi-Guang Huang
Zhi-Guang Huang
ZZZhe-Yue Zhou
Zhe-Yue Zhou
QLQiu-Wen Lou
Qiu-Wen Lou
ZZZhenhong Zhu
Zhenhong Zhu

7 September 2023 in Toxicon
Verified
Journal Article
Closed access
YYYi-Xuan Yang
Yi-Xuan Yang
XWXin-Yi Wang
Xin-Yi Wang
TLTong Lin
Tong Lin
YSYu Sun
Yu Sun
YYYi-Cheng Yu
Yi-Cheng Yu
ZZZhenhong Zhu
Zhenhong Zhu

17 September 2025 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
芯童芯锌 童
芯锌 童
DZDaixi Zhang
Daixi Zhang
ZZZhenhong Zhu
Zhenhong Zhu
Liquid–liquid phase separation (LLPS) is a fundamental biophysical process in which proteins and nucleic acids dynamically demix from the cellular milieu to form membraneless organelles (MLO) with liquid-like properties. Environmental cues, such as light, temperature fluctuations, and pathogen interactions, induce LLPS of fungal proteins with intrinsically disordered regions (IDRs) or multimerization domains, thereby regulating fungal hyphal growth, sexual reproduction, pathogenesis, and adaptation. Recently, LLPS has emerged as a powerful tool for biomolecular research, innovative biotechnological application, biosynthesis and metabolic engineering. This review focuses on the current advances in environmental cue-triggered fungal condensates assembled by LLPS, with a focus on their roles in regulating the fungal physical biology and cellular processes including transcription, RNA modification, translation, posttranslational modification process (PTM), transport, and stress response. It further discusses the strategies of engineering synthetic biomolecular condensates in microbial cell factories to enhance production and metabolic efficiency.

25 March 2024 in Research Square
Verified
Preprint
Open access
PDF file
XWXinyi Wang
Xinyi Wang
YYYixuan Yang
Yixuan Yang
WCWeiwei Chen
Weiwei Chen
LGLi Gan
Li Gan
YSYu Sun
Yu Sun
ZZZhenhong Zhu
Zhenhong Zhu
Momordica antiviral protein 30 kDa (MAP30) is a type I ribosome-inactivating protein (RIP) with antibacterial, anti-HIV and antitumor activities but lacks the ability to target tumor cells. To increase its tumor-targeting ability, the arginine-glycine-aspartic (RGD) peptide and the epidermal growth factor receptor interference (EGFRi) peptide were fused with MAP30, which was named ELRL-MAP30. The use of targeted therapy for triple-negative breast cancer (TNBC) MDA-MB-231 cells, which lack the expression of estrogen receptor (ER), Progesterone receptor (PgR) and human epidermal growth factor receptor-2 (HER2), is limited. In this study, we focused on exploring the effect and mechanism of ELRL-MAP30 on TNBC MDA-MB-231 cells. First, we discovered that ELRL-MAP30 significantly inhibited the migration and invasion of MDA-MB-231 cells and induced MDA-MB-231 cell apoptosis. Moreover, ELRL-MAP30 treatment significantly reduced Bcl-2 protein expression and increased BAX protein expression. Furthermore, ELRL-MAP30 triggered apoptosis via the Fak/EGFR/Erk and Ilk/Akt signaling pathways. In addition, recombinant ELRL-MAP30 can also inhibit chicken embryonic angiogenesis, indicating its potential therapeutic effects on tumor angiogenesis. Collectively, these results indicate that ELRL-MAP30 has significant tumor-targeting properties in MDA-MB-231 cancer cells and reveals potential therapeutic effects on angiogenesis. These findings indicate the potential role of ELRL-MAP30 in the targeted treatment of the TNBC cell line MDA-MB-231.